In an adult with severe insomnia for two weeks despite multiple oral agents and a nightly dose of suvorexant 10 mg, can emergency department staff safely induce sleep using intravenous medications?

Emergency IV Sleep Induction is NOT Recommended for Refractory Insomnia

The emergency department should not induce sleep with IV medications for this patient with severe refractory insomnia. This scenario requires urgent outpatient sleep medicine referral and optimization of oral pharmacotherapy, not procedural sedation.

Why IV Sleep Induction is Inappropriate

The available evidence does not support using IV sedation to "induce sleep" in patients with chronic insomnia. The practice guidelines for sedation and analgesia by non-anesthesiologists 1 address procedural sedation for medical procedures, not treatment of insomnia. Using IV benzodiazepines or propofol to force sleep:

• Does not treat the underlying insomnia disorder - it merely provides temporary unconsciousness
• Carries significant risks including respiratory depression, airway obstruction, and cardiovascular complications 1
• Has no evidence base for improving insomnia outcomes
• May worsen the problem by disrupting normal sleep architecture and potentially causing rebound insomnia

What the ER Should Actually Do

Immediate Assessment Priorities

The ER staff must first determine if this represents:

1. True complete sleep deprivation for 2 weeks (extremely rare and suggests an underlying medical/psychiatric emergency)
2. Severe insomnia with some sleep obtained (more likely, but patient perceives no sleep - paradoxical insomnia)
3. Acute psychiatric crisis requiring immediate intervention

Critical red flags to evaluate:

• Psychosis, mania, or severe mood disturbance suggesting bipolar disorder or psychotic depression
• Substance use (stimulants, caffeine excess, alcohol withdrawal)
• Acute medical conditions (hyperthyroidism, pain crisis, neurological emergency)
• Medication-induced insomnia (corticosteroids, stimulants, activating antidepressants)
• Sleep apnea or other primary sleep disorders

Appropriate ER Management

For optimization of oral therapy, the patient is currently on suvorexant 10 mg, which is at the lower end of the dosing range. According to FDA labeling 2, suvorexant can be increased to 20 mg (the maximum dose) if the 10 mg dose is well-tolerated but insufficiently effective. The ER physician could:

• Increase suvorexant to 15-20 mg for immediate use 3
• Add a short-acting benzodiazepine receptor agonist such as zolpidem 10 mg for sleep onset if the patient has difficulty falling asleep 3
• Consider adding low-dose doxepin 3-6 mg for sleep maintenance if wake after sleep onset is the primary problem 3

The 2017 AASM guidelines 3 support using these agents for insomnia, though all carry WEAK recommendations reflecting the quality of available evidence.

Medication Sequencing for Refractory Cases

According to the 2008 AASM consensus guidelines 4, when initial pharmacotherapy fails, the recommended sequence is:

1. Try alternate BzRA or ramelteon if the initial agent unsuccessful
2. Add sedating antidepressants (trazodone, doxepin, mirtazapine) - particularly if comorbid depression/anxiety
3. Combine BzRA with sedating antidepressant
4. Consider other sedating agents (gabapentin, quetiapine, olanzapine) only for patients with comorbid conditions that might benefit from these medications' primary actions 4

Important caveat: The guidelines explicitly state that barbiturates and chloral hydrate are NOT recommended 4, and trazodone actually has a negative recommendation in the 2017 guidelines 3 despite widespread off-label use.

Disposition and Follow-Up

The patient requires:

• Urgent sleep medicine referral (within 1-2 days, not weeks)
• Psychiatric evaluation if not already established, as severe refractory insomnia often has psychiatric comorbidity
• Cognitive behavioral therapy for insomnia (CBT-I) - this is the first-line treatment per multiple guidelines 4, 5 and should be initiated even when pharmacotherapy is used
• Short-term crisis management plan with optimized oral medications and close follow-up

The American College of Physicians guideline 5 emphasizes that pharmacologic treatment should use shared decision-making and be considered adjunctive to CBT-I, not a replacement.

Safety Considerations

Critical warnings about suvorexant from FDA labeling 2:

• Can cause next-day somnolence and impaired driving (dose-dependent)
• May cause complex sleep behaviors (sleep-walking, sleep-driving)
• Worsening depression and suicidal ideation reported 2, 6
• Should not be combined with strong CYP3A inhibitors 2

If the patient truly has had zero sleep for 2 weeks, this represents a medical emergency requiring psychiatric hospitalization, not ER-based IV sedation. Complete sleep deprivation of this duration would cause severe cognitive impairment, hallucinations, and potentially life-threatening complications.